Putin changes composition of Council for implementation of genetic technology development program

Another deputy head of the Ministry of Industry and Trade, Vasily Shpak, who, among other things, oversees the development of the electronics industry in his position, has also been excluded from the council. The council no longer includes the director of the State Scientific Center for Applied Microbiology and Biotechnology of Rospotrebnadzor Ivan Dyatlov, the chief researcher of the V.A. Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences Dmitry Kuprash, and the head of the Center for Genomic Research "Kurchatov Genome Center" Evgeny Sverdlov.

Deputy Minister of Industry and Trade Mikhail Yurin joined the council. In the department, he oversees issues of standardization and technical regulation, issues related to the use of the best available technologies in industry, and the work of the department of chemical-technological complex and bioengineering technologies.

Among others, the council includes the Russian Minister of Health Mikhail Murashko, the head of the Federal Medical and Biological Agency of Russia Veronika Skvortsova, the head of Rospotrebnadzor Anna Popova, the scientific director of the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences Viktor Vlasov, the general director of R-Pharm JSC Vasily Ignatyev, and the chairman of the board of directors of Biocad CJSC Dmitry Morozov. The chairperson of the council is Deputy Prime Minister Tatyana Golikova.

The Federal Program for the Development of Genetic Technologies was approved in 2019 by Dmitry Medvedev, who was then the Prime Minister of the Russian Federation. Initially, the program was supposed to be in effect until 2027, but in March 2022, Vladimir Putin ordered its extension until 2030. It was planned to allocate 127 billion rubles for the implementation of the federal program in 2019–2027, of which 115 billion were budget funds. The program envisages the creation of genomic research centers, the development of genetic editing technologies, the creation of scientific and technological groundwork for medicine, the improvement of the system for preventing biological emergencies and control in this area, as well as other activities.

One of the key partners of the government in the implementation of the program since 2020 is PJSC Rosneft. At the end of June 2025, Russian Prime Minister Mikhail Mishustin instructed Tatyana Golikova to conclude an additional agreement with PJSC in order to accelerate the solution of the tasks set.